Rein Therapeutics (RNTX) vs Spero Therapeutics (SPRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rein Therapeutics (RNTX) has outperformed Spero Therapeutics (SPRO) over the past year, losing 44.7% versus a loss of 50.0%. Over five years, SPRO leads with a -93.1% price change compared with -96.2% for RNTX. Spero Therapeutics is the larger company by market cap ($66.4 million vs $66.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNTX | SPRO |
|---|---|---|
| Share price | $0.7693 | $1.14 |
| Market cap | $66.37M | $66.39M |
| 1-day change | -2.46% | -2.56% |
| YTD return | -33.68% | -51.07% |
| 1-year return | -44.65% | -50.00% |
| 5-year return | -96.19% | -93.13% |
| P/E ratio (TTM) | — | 8.14 |
| EPS (TTM) | $-1.68 | $0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.18 | $3.08 |
| 52-week low | $0.694 | $1.08 |
| Distance from 52-week high | -64.71% | -62.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +679.93% | +338.60% |
| Average volume | 430.81K | 1.20M |
| Shares outstanding | 86.27M | 58.23M |
| Employees | 10 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Spero Therapeutics
SPRO stock →Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
RNTX vs SPRO FAQ
Which is bigger, Rein Therapeutics or Spero Therapeutics?
Spero Therapeutics (SPRO) is larger, with a market capitalization of $66.39M compared with $66.37M for Rein Therapeutics (RNTX).
Which stock has performed better over the past year, RNTX or SPRO?
RNTX returned -44.65% over the past 12 months, compared with -50.00% for SPRO (price return, excluding dividends). Past performance does not predict future results.
Are Rein Therapeutics and Spero Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.